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1607-551X/Copyright ª 2014, KaohsiuAbstract The combined effects of metabolic syndrome and the apolipoprotein E and CYP46
genotypes on the risk of cognitive decline has yet to be determined among Taiwanese Chinese.
Two hundred and nine mentally healthy middle-aged and older adults were assessed for meta-
bolic syndrome, cognitive function using the Cognitive Abilities Screening Instrument, Mini-
Mental State Examination, ApoE, and CYP46 polymorphisms. There were no differences in
cognitive performance, ApoE epsilon4 (ε4) carrier status, or CYP46 genotypes between partic-
ipants with and those without metabolic syndrome. The ε4 carriers and participants with the
AA allele of CYP46 had significantly lower mental manipulation score. Metabolic syndrome and
ε4 had synergistic effects on cognitive decline. Therefore, the ε4 carriers and participants with
the AA allele of CYP46 have decreased mental manipulation ability. The metabolic syndrome
may play a role in subtle cognitive dysfunction in ε4 carriers among Taiwanese Chinese.
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344 C.-L. Lai et al.Introduction
There is currently a great deal of interest in the prevention
of cognitive decline in the rapidly aging population. Ideally,
preventive strategies require the identification of a suitable
intervention approach. Alzheimer’s disease (AD) is the most
common cause of aged-related dementia [1,2]. Vascular
risk factors such as hypertension, diabetes, and dyslipide-
mia may reduce cerebral perfusion, increase oxidative
stress, or activate a neuroinflammatory response, all of
which can trigger amyloid production [3] which is a path-
ological hallmark of AD. Metabolic syndrome is a clustering
of cardiovascular and metabolic risk factors that increases
the risk of developing atherosclerotic cardiovascular dis-
ease and stroke [4,5]. Previous studies have suggested that
several of the individual components of metabolic syn-
drome are associated with cognitive impairment [6,7].
Nonetheless, although many studies suggest that the com-
bined effects of metabolic syndrome-associated vascular
risk factor may lead to a greater risk of cognitive decline, a
growing number of reports have conflicting results [8,9].
The apolipoprotein E gene (ApoE), localized on chro-
mosome 19, encodes cholesterol and other lipid trans-
porters [10]. It is produced abundantly in the brain, where
it appears to modulate neuritic growth [11], neuronal
repair, and the development of senile plaque, vascular
amyloid, and neurofibrillary tangle [12], which are all
considered significant in the pathogenesis of AD. Although
the distribution of ApoE alleles shows a wide variation
across ethnic groups, several studies have demonstrated a
relationship between ApoE ε4 and increased risk of cogni-
tive decline and dementia [13,14]. Furthermore, a growing
body of evidence supports the association between ApoE
polymorphisms, the early development of atherosclerosis,
and cardiovascular events [12]. Other studies also report an
association between ApoE polymorphisms and metabolic
syndrome [15]. However, whether or not the combined
effect of ε4 and metabolic syndrome increases the risk of
cognitive decline remains controversial [8,16].
The brain is the most cholesterol-rich organ in the body
and cholesterol metabolism has been implicated in the
pathogenesis of AD [17] through the accumulation of toxic
peptide b-amyloid. However, there is still no consensus
regarding the effect of cholesterol on cognitive decline or
dementia [18]. Cholesterol 24S hydroxylase (CYP46) is
encoded by the CYP46 gene, which is located in chromo-
some 14 and expressed exclusively in the brain [19]. Serum
cholesterol is almost completely unable to pass through the
bloodebrain barrier so brain cholesterol is synthesized
locally [20]. CYP46 regulates the elimination of excess
cholesterol from the brain into the periphery [21] and lower
CYP46 levels may lead to higher levels of brain cholesterol,
thereby affecting its homeostasis. This, in turn, may also be
involved in the pathogenesis of AD [22]. Recent studies
support a genetic association between the intron 2 poly-
morphism of the CYP46 gene and the risk of AD [21,23],
although other studies have not found this association [24].
The present study aimed to investigate the influence of
the metabolic syndrome and lipid-related genes (ApoE and
CYP46) on cognition and determine whether metabolic
syndrome and genotypes of ApoE and CYP46 have asynergistic effect on cognitive decline among Taiwanese
Chinese.Methods
Participants
Two hundred and nine healthy middle-aged and older adults
(age range, 56e81 years; 47% male; Taiwan Chinese
ethnicity) were recruited from among individuals under-
going regular health examinations at Kaohsiung Medical
University Hospital, Kaohsiung, Taiwan and in a community-
based setting. The participants received a comprehensive
medical evaluation including demographic data, history,
physical examination, blood chemistry, and cognitive
assessment. Resting blood pressure and fasting lipid and
glucose levels were determined. Waist circumference was
measured at the level of the iliac crest at minimal inspi-
ration to the closest 0.1 cm. Individuals with a previous
history or clinical evidence of neurologic (e.g., stroke,
epilepsy, Parkinson’s disease, dementia, traumatic brain
injury, multiple sclerosis, brain tumor) or psychiatric (e.g.,
schizophrenia, affective disorders, substance abuse) dis-
eases, and those with scores on the Cognitive Abilities
Screening Instrument (CASI) [25] below a cut-off value
adjusted by age and educational level were excluded. All of
the participants were assessed for characteristics of
metabolic syndrome and ApoE and CYP46 polymorphisms
after providing informed consent.
Cognitive assessment
The participants’ cognitive abilities were assessed using a
Chinese version of the CASI [25], conducted by research
assistants. The CASI included a 25-item test divided into
nine cognitive domains of attention, mental manipulation,
orientation, short-term memory, long-term memory, lan-
guage ability, constructional praxis, category fluency, and
abstraction and judgment. The maximum score was 100,
with higher scores indicating better ability. For each
participant, the total CASI score and the nine domain scores
were calculated. Some of the CASI items are comparable to
items used in the Mini-Mental State Examination (MMSE).
Thus, a CASI-estimated MMSE score (MMSE-CE) [25] was also
calculated.
Metabolic syndrome
Metabolic syndrome was defined using the modified version
of the criteria introduced by the National Cholesterol Ed-
ucation Program - Adult Treatment Program III (NAEP-
ATPIII) [26] as the presence of three or more of the
following: fasting plasma glucose level  110 mg/dL or drug
treatment for elevated glucose level; serum triglyceride
level  150 mg/dL; serum high-density lipoprotein choles-
terol (HDL-C) level < 40 mg/dL for men and <50 mg/dL for
women; blood pressure  130/85 mmHg or antihyperten-
sive medication use; and a waist circumference > 90 cm for
men or > 80 cm for women [27].







Ages (y)a 68.62  7.16 67.53  6.63 0.3037
Sex (M/F)b 30/35 75/69 0.4274
Education (y)a 10.58  3.74 11.29  3.97 0.2151
MMSE (score)a 25.97  2.47 26.26  2.37 0.4313
CASI-T (score)a 90.09  4.74 90.53  4.50 0.5334
ATT (score) 6.83  1.10 7.10  0.95 0.0853
MENMA (score) 8.38  1.47 8.41  1.66 0.9126
ORI (score) 17.65  0.67 17.77  0.93 0.2745
STM (no.) 9.06  2.07 9.22  1.78 0.5841
LTM (no.) 10.00  0.00 10.01  0.19 0.6563
LAN (no.) 9.74  0.49 9.66  0.55 0.2893
DRA (score) 9.80  1.02 9.85  0.86 0.7460
FLU(no.) 7.66  2.10 7.46  1.89 0.5058
A&J (score) 10.54  1.62 10.73  0.97 0.2196
ApoE ε4D, n (%)b 9 (13.85) 22 (15.28) 0.7875
CYP46, n (%)b
AA 27 (41.54) 58 (40.28) 0.8636
AG/GG 38 (58.46) 86 (59.72)
A&J Z abstraction and judgment; APOE Z apolipoprotein E;
ATT Z attention; CASI Z cognitive abilities screening instru-
ment; CYP46 Z 24S-cholesterol hydroxylase;
DRA Z constructional praxis; F Z female; FLU Z category
fluency; LAN Z language ability; LTM Z long-term memory;
M Z male; MENMA Z mental manipulation; MeSy Z metabolic
syndrome; MMSE Z Mini-Mental State Examination;
ORI Z orientation; STM Z short-term memory.
a By analysis of variance (ANOVA).
b By Chi-square test.
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Genomic DNA was extracted from peripheral blood leuko-
cytes using a QIAmp blood kit (QIAGEN). Exon 4 of the ApoE
gene was amplified by polymerase chain reaction (PCR)
with an upstream primer, 50-
TCGCGGGCCCCCGGGCCTGGTACA-30 and a downstream
primer, 50- ACAGAATTCGCCCCGGCCTGGTACACTGCCA-30
[28]. The PCR products were digested with HhaI and the
fragments were separated by electrophoresis on a 6%
polyacrylamide gel, followed by ethidium bromide staining.
The DNA fragments were visualized by UV illumination. The
ApoE genotypes were determined in a blinded fashion by
scoring for a unique combination of fragment sizes, as
described by Wenham et al. [28]. Allele frequencies were
estimated by counting the alleles and calculating sample
proportions.
CYP46 genotype
Genomic DNA was extracted from whole blood samples
using a standard procedure. Information on single-
nucleotide polymorphisms (SNP) involved in this study can
be found in a public database (http://www.hapmap.org, ID
rs754203). Genotypes were determined by real-time PCR
and confirmed by DNA sequencing. The rs754203 was
located on an A to G SNP in intron 2 of the CYP46 gene. For
this SNP, the forward primer was 50-GGGACAATCAAA-
GAAGGAG-30 and the reverse primer was 50-AACCAAAGT-
GACCCGAAG- 30. The PCR product was digested with MspI.
The CYP46 G allele generated two fragments of 114 bp,
whereas the CYP46 A allele resulted in an uncut fragment of
254 bp.
Statistical analysis
Analysis of variance (ANOVA) and Chi-square test were used
to compare the characteristics of demographic data and
measurements of cognitive assessment between partici-
pants with and those without metabolic syndrome or ε4 and
CYP46 genotypes. The effects of the interaction between
metabolic syndrome, ε4 and CYP46 genotypes on cognitive
measurements were evaluated by two-way analysis of
covariance (ANCOVA), with age, sex, and educational level
as covariates. Statistical significance was set at p < 0.05.
Results
When the participants were stratified according to the
presence of metabolic syndrome, there were no differences
in demographic characteristics, MMSE-CE scores, CASI total
scores, all CASI sub-scores, or the percentages of ε4 carriers
and CYP46 genotypes (Table 1).
The demographic characteristics, MMSE-CE scores, CASI
scores, percentages of metabolic syndrome, and CYP46
genotypes were compared according to the presence or
absence of the ε4 allele, with carriers and noncarriers
revealing similar values for most items (Table 2). However,
the ε4 carriers had a significantly decreased mean score of
mental manipulation compared with nonε4 carriers(8.32  1.63 vs. 8.87  1.28), but there was no significant
difference in the CASI total score between the two groups.
When the participants were stratified according to
CYP46 genotypes, there was a significantly lower score of
mental manipulation in participants with the AA CYP46
genotype compared with those with the AG/GG CYP46 ge-
notypes (8.09  1.64 vs. 8.61  1.53; Table 3). There were
no significant differences in demographic characteristics,
MMSE-CE scores, CASI total scores, components of meta-
bolic syndrome, or percentages of metabolic syndrome and
ε4 carriers between the two groups (Table 3).
The statistical results using ANCOVA with age, sex, and
educational level as covariates for the interactive effects
of metabolic syndrome and the presence of ε4 and CYP46
genotypes as measures of cognition are summarized in
Tables 4 and 5. There was a significantly combined effect in
mental manipulation score and a marginal effect in the
CASI total score between the metabolic syndrome and ε4
carriers. However, there was no interactive effect of
metabolic syndrome and CYP46 polymorphism on CASI and
MMSE-CE scores.
Discussion
The present study has several main findings. Firstly, there is
no association between metabolic syndrome and cognitive
performance by CASI score. Secondly, the ε4 carriers and







Ages (y)a 66.74  5.58 68.07  6.99 0.2469
Sex (M/F)b 15/16 90/88 0.8232
Education (y)a 11.21  3.59 11.04  3.97 0.8133
MMSE (score)a 26.81  2.20 26.06  2.42 0.0912
CASI-T (score)a 91.03  4.56 90.28  4.58 0.4027
ATT (score) 7.13  1.02 7.00  1.01 0.5202
MENMA (score) 8.32  1.63 8.87  1.28 0.0401
ORI (score) 17.74  0.51 17.73  0.91 0.9197
STM (no.) 9.11  2.02 9.18  1.85 0.8551
LTM (no.) 10.00  0.00 10.0 1  0.17 0.6560
LAN (no.) 9.71  0.57 9.68  0.53 0.7897
DRA (score) 9.71  1.30 9.85  0.83 0.5533
FLU(no.) 7.45  2.29 7.53  1.90 0.8515
A&J (score) 10.81  0.91 10.65  1.02 0.3785
MeSy, n (%)b 9 (29.03) 56 (31.46) 0.7875
CYP46, n (%)b
AA 12 (38.71) 73 (41.01) 0.8097
AG/GG 19 (61.29) 105 (58.99)
A&J Z abstraction and judgment; APOE Z apolipoprotein E;
ATT Z attention; CASI Z cognitive abilities screening instru-
ment; CYP46 Z 24S-cholesterol hydroxylase;
DRA Z constructional praxis; F Z female; FLU Z category
fluency; LAN Z language ability; LTM Z long-term memory;
M Z male; MENMA Z mental manipulation; MeSy Z metabolic
syndrome; MMSE Z Mini-Mental State Examination;
ORI Z orientation; STM Z short-term memory.
a By analysis of variance (ANOVA).
b By Chi-square test.
Table 3 Characteristics of participants by presence of
CYP46 genotypes.
AA (n Z 85) AG/GG (n Z 124) p
Ages (y)a 67.82  7.14 67.90  6.59 0.9349
Sex (M/F)b 41/44 64/60 0.6314
Education (y)a 10.88  3.93 11.19  3.90 0.5753
MMSE (score)a 25.88  2.38 26.36  2.40 0.1550
CASI-T (score)a 89.92  4.57 90.72  4.56 0.2151
ATT (score) 7.05  1.10 7.00  0.94 0.7484
MENMA (score) 8.09  1.64 8.61  1.53 0.0226
ORI (score) 17.64  1.00 17.79  0.75 0.2618
STM (no.) 9.22  1.79 9.14  1.94 0.7473
LTM (no.) 9.99  0.11 10.02  0.18 0.1639
LAN (no.) 9.70  0.49 9.67  0.56 0.6099
DRA (score) 9.89  0.79 9.79  0.99 0.4007
FLU(no.) 7.36  1.94 7.63  1.96 0.3373
A&J (score) 10.64  0.97 10.69  1.02 0.6776
MeSy, n (%)b 27 (31.76) 38(30.65) 0.8636
ApoE ε4D, n (%)b 12 (14.12) 19(15.32) 0.8097
A&J Z abstraction and judgment; APOE Z apolipoprotein E;
ATT Z attention; CASI Z Cognitive Abilities Screening Instru-
ment; CYP46 Z 24S-cholesterol hydroxylase;
DRA Z constructional praxis; F Z female; FLU Z category
fluency; LAN Z language ability; LTM Z long-term memory;
M Z male; MENMA Z mental manipulation; MeSy, metabolic
syndrome; MMSE Z Mini-Mental State Examination;
ORI Z orientation; STM Z short-term memory.
a By analysis of variance (ANOVA).
b By Chi-square test.
346 C.-L. Lai et al.participants with the AA allele of CYP46 have significantly
lower mental manipulation scores, although there are no
significant differences in the CASI total and MMSE scores.
Thirdly, there is a synergistic effect of the metabolic syn-
drome and ε4 on subtle cognitive dysfunction. As regards
the neuro-psychological tests, the MMSE, although used
most commonly in community-based epidemiologic studies
[29], is limited in its ability to discriminate cognitive
decline in nondemented participants. However, the CASI
total score can be used as a summary index of basic
cognitive skills and is useful for detecting dementia and
mild cognitive impairment [25].
The diversity in study populations in terms of age and
ethnicity, severity of individual components, time of
exposure, and the use of medications may explain these
variations. However, a more complex association is also
likely. The lack of a clear definition of metabolic syndrome
is due to an unclear pathogenesis [30] and this is another
limitation. Further studies with long-term follow-up and
serial assessments of metabolic syndrome are needed to
further clarify the relationships found here.
The significantly lower mental manipulation score of the
ε4 carriers is not surprising because the CASI total scores
did not show a difference in participants with or without ε4.
This finding is in line with a previous study using cognitive
event-related potentials [8]. Neuroimaging studies using
positron emission tomography and functional magneticresonance imaging (MRI) also support the association of the
ε4 allele with functional brain abnormalities in participants
with intact cognition [31,32].
However, there are still discrepancies in the literature
regarding the impact of ApoE ε4 on cognitive decline in
normal adults [14]. One reason for this discrepancy is that
genetic effects on cognition are complex, with a possible
involvement of several genes and a synergistic interaction
with environmental factors [14]. Other explanations
include age, ethnicity, sample size, and variability of the
testing instruments. Cognition involves several domains and
recent reports demonstrate that ApoE ε4 has rather specific
and small adverse effects on cognitive performance [14].
Various neuro-psychological tests have been used as an
index of cognitive function. However, these are also limited
by “floor or ceiling” effects, which involve limited sensi-
tivity in very mildly impaired participants.
There is a significant combined effect in mental
manipulation score and a marginal effect in the CASI total
score between metabolic syndrome and ε4 carriers in the
present study. Dyslipidemia is a critical diagnostic compo-
nent of metabolic syndrome [33]. Various ApoE genotypes
have different effects on cholesterol metabolism and can
influence the risk of cognitive decline through fluctuations
in brain cholesterol homeostasis [12]. Most studies support
the association of hypertension and diabetes with increased
risk of cognitive decline and dementia [34].
Moreover, a previous study suggests that the impact of
metabolic syndrome or individual components of metabolic
syndrome on structural MRI of the brain differs according to
Table 4 Characteristics of participants by presence of metabolic syndrome and apolipoprotein E ε4.
Metabolic syndrome Nonmetabolic syndrome p
ApoE ε4þ (n Z 9) ε4e (n Z 56) ε4þ (n Z 22) ε4e (n Z 122) MeSy ε4 MeSyaε4
MMSE (score) 25.78  2.39 26.00  2.50 27.23  2.02 26.08  2.39 0.1720 0.5294 0.1452
CASI-T (score) 88.86  5.70 90.40  4.57 92.05  3.70 90.25  4.60 0.1039 0.7692 0.0505
ATT (score) 6.78  0.97 6.84  1.12 7.27  1.03 7.07  0.94 0.1850 0.9131 0.5823
MENMA (score) 8.00  1.41 8.45  1.48 9.23  1.07 8.26  1.70 0.2093 0.4418 0.0484
ORI (score) 17.67  0.50 17.64  0.70 17.77  0.53 17.77  0.99 0.5287 0.9052 0.9372
STM (no.) 8.28  3.04 9.19  1.87 9.45  1.37 9.18  1.85 0.2463 0.2630 0.1299
LTM (no.) 10.00  0.00 10.00  0.00 10.00  0.00 10.01  0.20 0.9261 0.7994 0.9410
LAN (no.) 9.89  0.22 9.71  0.51 9.63  0.65 9.66  0.53 0.0981 0.6599 0.3431
DRA (score) 9.22  2.33 9.89  0.59 9.91  0.43 9.84  0.92 0.1167 0.1024 0.0534
FLU(no.) 6.78  2.54 7.80  2.01 7.73  2.19 7.41  1.84 0.9048 0.4218 0.1751
A&J (score) 10.56  0.73 10.54  1.11 10.91  0.97 10.70  0.97 0.3532 0.6248 0.7267
A&J Z abstraction and judgment; APOE Z apolipoprotein E; ATT Z attention; CASI Z Cognitive Abilities Screening Instrument;
DRA Z constructional praxis; F Z female; FLU Z category fluency; LAN Z language ability; LTM Z Long-Term Memory; M Z male;
MENMAZ mental manipulation; MeSyZ metabolic syndrome; MMSEZ Mini-Mental State Examination; ORIZ orientation; STMZ short-
term memory.
a 2-way analysis of covariance (ANCOVA) with age, sex, and educational level as covariate.
Metabolic syndrome and gene on cognition 347the ApoE genotype [35]. To complicate matters, possession
of one or more ε4 alleles further increases the risk of de-
mentia. Therefore, although this study implies that meta-
bolic syndrome may play a role in subtle cognitive
dysfunction in the presence of the ApoE ε4 allele among
Taiwanese Chinese, large-scale and cohort studies are still
necessary to further confirm such an interaction.
The present study shows that participants with the AA
allele of CYP46 have significantly lower mental manipula-
tion scores and that there is no interactive effect between
metabolic syndrome and CYP46 genotypes on cognition.
Previous studies have reported that CYP46 polymorphism is
associated with an increased b-amyloid load in the brain
[36] and is a genetic risk for AD [21,23] via cholesterol
metabolism. Findings of a longitudinal study suggest that
CYP46 genotypes may play a role in modulating the courseTable 5 Characteristics of participants by presence of metabol
Metabolic syndrome Non
CYP46 AA (n Z 27) AG/GG (n Z 38) AA (n Z
MMSE (score) 25.93  2.04 26.00  2.76 25.86 
CASI-T (score) 90.37  3.80 89.89  5.34 89.71 
ATT (score) 6.81  1.21 6.84  1.03 7.16 
MENMA (score) 8.33  1.47 8.42  1.48 7.98 
ORI (score) 17.52  0.85 17.74  0.50 17.71 
STM (no.) 9.46  1.54 8.78  2.35 9.11 
LTM (no.) 10.00  0.00 10.00  0.00 9.98 
LAN (no.) 9.79  0.37 9.70  0.56 9.67 
DRA (score) 10.00  0.00 9.66  1.32 9.84 
FLU(no.) 7.48  1.95 1.79  2.22 7.31 
A&J (score) 10.74  1.02 10.39  1.08 10.59 
A&J Z abstraction and judgment; ATT Z attention; CASI Z Cognit
droxylase; DRA Z constructional praxis; F Z female; FLU Z catego
M Z male; MENMA Z mental manipulation; MeSy Z metabolic syndro
STM Z short-term memory.
a 2-way analysis of covariance (ANCOVA) with age, sex and educatioof cognitive decline in later life [23]. A neuroimaging study
also supported the association of the CYP46 AA allele with
the severity of white matter lesions in individuals with mild
cognitive impairment [37].
However, an increasing body of evidence suggests a link
between cholesterol turnover and AD [24]. Moreover,
despite advances in research on the pathogenesis and risk
factors that predispose to AD and cognitive decline, many
key aspects remain unclear. At present, the relationship
among cholesterol levels, CYP46 polymorphisms, and
cognition is less understood [3,24]. The inconsistent results
are mainly attributable to the effect of geneegene and
geneeenvironmental interactions. Furthermore, the poly-
genic nature of metabolic syndrome and the related car-
diovascular risk factors suggest that a single gene is unlikely
to be responsible for the development of cognitive declineic syndrome and CYP46 genotypes.
metabolic syndrome p
58) AA/AG (n Z 86) MeSy CYP MeSyaCYP
2.54 26.52  2.22 0.5287 0.3137 0.4209
4.91 91.08  4.15 0.8047 0.4037 0.4988
1.04 7.07  0.90 0.1274 0.9392 0.2212
1.72 8.70  1.56 0.6926 0.0922 0.2880
1.06 17.81  0.83 0.3064 0.2296 0.7185
1.89 9.30  1.71 0.9492 0.4338 0.3153
0.13 10.02  0.22 0.9354 0.3420 0.5002
0.53 9.65  0.57 0.1730 0.6370 0.9436
0.95 9.85  0.80 0.9431 0.2527 0.2682
1.96 7.56  1.84 0.2550 0.3702 0.6764
0.96 10.83  0.97 0.4865 0.7373 0.0970
ive Abilities Screening Instrument; CYP46 Z 24S-cholesterol hy-
ry fluency; LAN Z language ability; LTM Z long-term memory;
me; MMSE Z Mini-Mental State Examination; ORI Z orientation;
nal level as a covariates.
348 C.-L. Lai et al.[38]. Nevertheless, variations in age, ethnicity, and meth-
odology may also be involved.
There are some limitations to this study. Firstly, no data
were available on the use of lipid-lowering medications.
Previous studies have proposed that the effect of cholesterol
level on cognition is bidirectional due to the influence of age
[3]. The use of statins, a type of lipid-lowering drug, has also
been reported to possibly reduce the risk of cognitive decline
and developing AD [39], although the results are conflicting
[40]. A long-term cohort studywith treatmentmodification is
needed to further clarify this effect. Secondly, regarding the
decline in perception and psychomotor performance with
increasing age, previous reports have shown an age-related
effect on neuro-psychological tests [29]. Thus, the CASI and
MMSE-CE scores have been analyzed with age as a covariate
to reduce the influence of age in this study. Lastly, the rela-
tively small sample size and cross-sectional design may have
contributed to the marginal effect on cognition. Indeed, this
phenomenonmay be a diluted effect. As the participants are
healthy according to clinical criteria, some with the risk
genes will never develop dementia and somewithout the risk
genes will eventually develop dementia. Furthermore, the
CASI domain scores should be interpreted with more caution
than the CASI total score because the domain scores are
based on a smaller number of test items [25].
In conclusion, the present study reveals that ε4 carriers
and individuals with the AA allele of CYP46 have decreased
mental manipulation scores. There is also a combined ef-
fect of metabolic syndrome and ApoE ε4 alleles in subtle
cognitive dysfunction among the Taiwanese Chinese popu-
lation. Studies with long-term follow-up and serial assess-
ments of metabolic syndrome may provide information to
determine if both the metabolic syndrome and lipid-related
genes increase the risk of cognitive decline.Acknowledgments
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